Amgen, Kleiner Perkins Spin-Out Atara Sails Into The Spotlight
This article was originally published in The Pink Sheet Daily
Launched in fall 2012 via a partnership between Amgen and Kleiner Perkins Caufield & Byers, the Bay Area biotech has three subsidiary companies housing six biologic assets that used to belong to Amgen. With two financing rounds this year totaling $58.5 million, three candidates are slated to enter the clinic by 2015.
You may also be interested in...
The newest company created under the Atlas Venture Development Corp. model, Annovation, will develop a next-generation anesthetic through proof-of-concept, with investor The Medicines Co. holding an option to acquire the new company.
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
The deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.